Robert Schultze, MD
Ophthalmology · Slingerlands, NYNPI 1417933540
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Biotissue Holdings Inc. at 50.9% of the total. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 760 payments — averaging $195.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$76K
- Sun Pharmaceutical Industries Inc.$25K
- Kala Pharmaceuticals, Inc.$22K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Alcon$4K
- AbbVie$2K
- plus $11K from 28 others
Across 2 payments — averaging $2357.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$3K
- Alcon Research LLC$2K
What the payments were for
- Consulting fees$76,05351%
- Speaking & faculty fees$44,02530%
- Travel & lodging$7,0685%
- Food & beverage$21,56614%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$20,707
- INVELTYS$17,550
- Prokera$11,573
- LOTEMAX SM$8,916
- EYSUVIS$4,165
- BROMSITE$3,226
- Flarex$1,250
- Clareon$400
- TYRVAYA$398
- AmnioGraft$285
- Photrexa Viscous and Photrexa$283
- AcrySof IQ PanOptix$275
- Tecnis Simplicity$223
- RXSIGHT CONTACT LENS$219
- RXSIGHT INJECTOR CARTRIDGE$219
- RXSIGHT INJECTOR HANDPIECE$219
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$219
- LIGHT ADJUSTABLE LENS (LAL)$219
- CE-marked KXLA system$198
- OMNI(R) SURGICAL SYSTEM (US)$147
How this compares
$148,758 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $688,763 |
| RestasisCyclosporine | 241 | $355,873 |
| TyrvayaVarenicline Tartrate | 167 | $128,963 |
| Cyclosporine | 206 | $94,333 |
| MieboPerfluorohexyloctane/Pf | 69 | $90,051 |
| XiidraLifitegrast | 50 | $76,563 |
| Loteprednol Etabonate | 407 | $67,742 |
| CequaCyclosporine | 59 | $67,269 |
| Prednisolone Acetate | 1,797 | $55,825 |
| VevyeCyclosporine | 40 | $33,103 |
| LumiganBimatoprost | 48 | $28,327 |
| Bromfenac Sodium | 245 | $25,111 |
| Restasis MultidoseCyclosporine | 11 | $20,318 |
| ValacyclovirValacyclovir Hcl | 208 | $12,452 |
| LotemaxLoteprednol Etabonate | 30 | $12,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $436 | $688,76320 claims |
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $1,501 | $410,787326 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Zirgan | $1,383 | $173,765135 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,021 | $128,963167 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Lotemax Sm | $9,510 | $84,065454 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $25,180 | $67,26959 claims |
| Harrow Eye, LLCVevye | $123 | $33,10340 claims |
| AlconSimbrinza | $3,596 | $3,97019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Slingerlands
- Steven SimmonsSlingerlands$340K
- Michael BelinSlingerlands$65K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.